1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Horizon Scores In Second Round Of Sjögren’s Trial A Month After Amgen Buyout

 
• By Alaric DeArment

The company announced positive results in the second population of its Phase II study of dazodalibep in patients with Sjögren’s syndrome. Amgen is buying Horizon for $27.8bn.

Horizon announced successful results from its Phase II study of dazodalibep in Sjögren's syndrome • Source: Shutterstock

Horizon Therapeutics plc has scored a second win in its Phase II trial of dazodalibep in patients with Sjögren’s syndrome (SS) as the study has met its primary endpoint in another patient population, following an earlier success in September. The trial results mean the company can bring the drug into Phase III clinical development in 2023, sooner than it had anticipated while also providing further support for Amgen, Inc.’s nearly $28bn bid to take over Horizon.

Horizon said 18 January that the trial had met its primary endpoint of showing an improvement in the European Alliance of Associations for Rheumatology (EULAR) SS Patient Reported Index (ESSPRI) score among patients with moderate-to-severe

More from Clinical Trials

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

More from R&D

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.

In Brief: Positive New Data For Aptose’s Triplet Therapy In 1L AML

 
• By Sushmita Panda

Aptose’s tuspetinib triplet shows early mutation-agnostic promise in new data from Phase I/II program for frontline acute myeloid leukemia.